Abstract
Open reduction and internal fixation (ORIF) of mandibular fractures is frequently followed by pain, swelling, and trismus arising from surgical and traumatic tissue injury. Dexamethasone, a long-acting glucocorticoid, is commonly used to limit this inflammatory response, and may be delivered either as a submucosal depot at the operative site or combined with local anaesthetic as a Twin-Mix solution given as a regional nerve block. Direct prospective comparison of these two delivery methods in mandibular fracture surgery is limited. To assess clinical outcome of 2 different modalities of dexamethasone usage on postoperative symptoms following Open Reduction Internal Fixation in fractures of mandible and to document any complications related with the use of Dexamethasone both submucosally and as an Intraspace injection. Thirty-two patients requiring ORIF for unilateral or bilateral mandibular fractures were allocated to two equal groups. Group A patients received 4 mg submucosal dexamethasone at the surgical site immediately after wound closure; Group B patients received Twin-Mix solution (4% articaine with adrenaline plus 4 mg dexamethasone) as an intraspace inferior alveolar nerve block prior to surgery. Pain (visual analog scale), analgesic consumption, maximum interincisal opening, facial oedema (five-line technique), neurosensory status, and patient satisfaction (five-point Likert scale) were recorded at predefined postoperative intervals up to seven days, with neurosensory follow-up to 28 days. Statistical comparisons used the Mann-Whitney U, independent and paired t-tests, and chi-square tests, with p<0.05 considered as significant. Baseline demographic and fracture characteristics were comparable between groups. From postoperative day 1 onward, Group B patients recorded significantly lower pain scores than Group A (day 1, p=0.0026; day 2, p=0.0001; day 3, p=0.0009; day 7, p=0.0184), with significantly lower total analgesic consumption (4.75 ± 1.44 versus 7.81 ± 2.21 tablets; p=0.0003). Mouth opening improved progressively in both groups, reaching statistical significance earlier in Group B (day 3, p=0.0010) than Group A (day 7, p=0.0020), though intergroup differences at each time point were not significant. Facial oedema peaked on postoperative day 1 in both groups, with significant resolution by day 7 (Group A, p=0.0042; Group B, p=0.0001), again without significant intergroup difference. Neurosensory recovery was comparable between groups at all time points. Patient satisfaction was significantly higher in Group B at every assessment day (p<0.05). One patient in Group A developed postoperative infection, managed successfully with antibiotics and tooth extraction. Both submucosal dexamethasone and Twin-Mix solution were effective in reducing postoperative morbidity following mandibular fracture fixation. Twin-Mix solution conferred additional benefit through superior pain control, reduced analgesic requirement, earlier functional recovery of mouth opening, and higher patient satisfaction, suggesting it may be the preferable route when a regional block is already indicated for the surgical procedure.